Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% provides a hyperosmotic solution for peritoneal dialysis. Dextrose generates an osmotic gradient across the peritoneal membrane, promoting fluid and solute removal (ultrafiltration). Low calcium content helps manage hypercalcemia in patients requiring peritoneal dialysis.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal: 2-3 L per exchange, 4-5 exchanges daily, as prescribed by physician based on body size and residual renal function.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable; drug is not systematically absorbed. Dextrose has half-life of ~1.5-2 hours after absorption.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Primarily removed via peritoneal dialysis; negligible renal excretion due to local administration. Dextrose is metabolized systemically; dialysate is drained as waste.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution